| RMC-9805 : RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial Data |
AZD0530: Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer
E3ligase signal
For example, the structure of another HIV protease inhibitor tipranavir is shown on the left.
